TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
63 hedge funds and large institutions have $21M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 23 closing their positions.
191% more call options, than puts
Call options by funds: $545K | Put options by funds: $187K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less funds holding
Funds holding: 81 → 63 (-18)
35% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 23
53% less capital invested
Capital invested by funds: $45M → $21M (-$24.1M)
78% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$640K |
| 2 |
Citigroup
New York
|
+$638K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$258K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$67.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$56.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$3.42M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.35M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$490K |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$467K |
| 5 |
BlackRock
New York
|
-$317K |
TCRR Hedge Fund Activity: Q4 2022 in Review
63 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2022, worth a combined $21M — down 53% from $45M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TCRR and 5 opened new positions — a net loss of 18 holders — while 23 trimmed existing stakes and 15 added.
The largest buyer was Newtyn Management, adding an estimated $640K. The largest seller was K2 Principal Fund, exiting entirely with an estimated $3.42M sold.
- 63 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2022, down from 81 in Q3 2022.
- Funds reported $21M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2022, down 53% quarter-over-quarter.
- 5 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2022 and 23 closed out, a net change of -18 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2022 was Newtyn Management, an estimated $640K added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2022 was K2 Principal Fund, an estimated $3.42M sold.
Based on aggregated 13F filings for Q4 2022.